Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

References

• Borowitz M, Chan J. B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Organization for Research on Cancer; 2017.
   Google Scholar
• Jaso J, Thomas DA, Cunningham K, et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer. 2011 Sep 1;117(17):4009–4017. PubMed PMID: 21365622; PubMed Central PMCID: PMCPMC5548124.
   PubMed Web of Science ®Google Scholar
• Primo D, Tabernero MD, Perez JJ, et al. Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia. 2005 May;19(5):713–720. PubMed PMID: 15789066.
   PubMed Web of Science ®Google Scholar
• Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):392–399. PubMed PMID: 25527562; PubMed Central PMCID: PMCPMC4349279.
   PubMed Web of Science ®Google Scholar
• Hunger SP. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am Soc Hematol Educ Program. 2011;2011:361–365. PubMed PMID: 22160058.
   PubMed Web of Science ®Google Scholar
• Chopade P, Akard LP. Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):710–723. PubMed PMID: 30093283.
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making. Curr Hematol Malig Rep. 2018 Jun;13(3):202–211. PubMed PMID: 29687320; PubMed Central PMCID: PMCPMC6023770.
   PubMed Web of Science ®Google Scholar
• Radich JP, Mauro MJ. Tyrosine kinase inhibitor treatment for newly diagnosed chronic myeloid leukemia. Hematol Oncol Clin North Am. 2017 Aug;31(4):577–587. PubMed PMID: 28673389.
   PubMed Web of Science ®Google Scholar
• Hathaway L, Sen JM, Keng M. Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date. Patient Relat Outcome Meas. 2018;9:329–337. PubMed PMID: 30323696; PubMed Central PMCID: PMCPMC6173178.
   PubMed Web of Science ®Google Scholar
• Sawalha Y, Advani AS. Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int J Hematol Oncol. 2018 Mar;71:IJH02. PubMed PMID: 30302234; PubMed Central PMCID: PMCPMC6176956.
   PubMedGoogle Scholar
• Yurkiewicz IR, Muffly L, Liedtke M. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Drug Des Devel Ther. 2018;12:2293–2300. PubMed PMID: 30087554; PubMed Central PMCID: PMCPMC6063246.
   PubMed Web of Science ®Google Scholar
• Phelan KW, Advani AS. Novel therapies in acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2018 Aug;13(4):289–299. PubMed PMID: 30078158.
   PubMed Web of Science ®Google Scholar
• Leonard JT, Hayes-Lattin B. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia; current evidence, and improving outcomes going forward. Curr Hematol Malig Rep. 2018 Jul 14;13:329–340. PubMed PMID: 30008035; PubMed Central PMCID: PMCPMC6097057.
   PubMed Web of Science ®Google Scholar
• Hefazi M, Litzow MR. Recent advances in the biology and treatment of T cell acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2018 Aug;13(4):265–274. PubMed PMID: 29948644.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Kantarjian H, Ravandi-Kashani F, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol. 2018 Mar;16(3):216–223. PubMed PMID: 29742077
   PubMed Web of Science ®Google Scholar
• Gokbuget N. Treatment of older patients with acute lymphoblastic leukaemia. Drugs Aging. 2018 Jan;35(1):11–26. PubMed PMID: 29256044.
   PubMed Web of Science ®Google Scholar
• Stevenson M, Pandor A, Hamilton J, et al. Ponatinib for treating acute lymphoblastic leukaemia: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018 Jul;36(7):759–768. PubMed PMID: 29502175.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2018 Nov 5. doi: 10.1002/ajh.25338. PubMed PMID: 30394566.
   Web of Science ®Google Scholar
• Forsberg MH, Das A, Saha K, et al. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Ther Clin Risk Manag. 2018;14:1573–1584. PubMed PMID: 30233192; PubMed Central PMCID: PMCPMC6130274.
   PubMed Web of Science ®Google Scholar
• McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011 Sep 10;71(13):1771–1795. PubMed PMID: 21902298.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Saglio G, Atallah E, et al. Dasatinib dose management for the treatment of chronic myeloid leukemia. Cancer. 2018 Apr 15;124(8):1660–1672. PubMed PMID: 29370463; PubMed Central PMCID: PMCPMC5901015.
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658–6661. PubMed PMID: 15615512.
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005 Oct 15;65(20):9185–9189. PubMed PMID: 16230377.
   PubMed Web of Science ®Google Scholar
• Spijkers-Hagelstein JA, Mimoso Pinhancos S, Schneider P, et al. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia. 2013 Apr;27(5):1063–1071. PubMed PMID: 23334362.
   PubMed Web of Science ®Google Scholar
• Sarno J, Savino AM, Buracchi C, et al. SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. Oncotarget. 2018 May 1;9(33):22872–22885. PubMed PMID: 29796158; PubMed Central PMCID: PMCPMC5955419.
   PubMedGoogle Scholar
• Reyes-Sebastian J, Montiel-Cervantes LA, Reyes-Maldonado E, et al. Cell proliferation and inhibition of apoptosis are related to c-Kit activation in leukaemic lymphoblasts. Hematology. 2018 Sep;23(8):486–495. PubMed PMID: 29495952.
   PubMed Web of Science ®Google Scholar
• Leonard JT, Rowley JS, Eide CA, et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016 Aug 31;8(354):354ra114. PubMed PMID: 27582059.
   PubMed Web of Science ®Google Scholar
• Acharya M, Edkins AL, Ozanne BW, et al. SDF-1 and PDGF enhance alphavbeta5-mediated ERK activation and adhesion-independent growth of human pre-B cell lines. Leukemia. 2009 Oct;23(10):1807–1817. PubMed PMID: 19609283.
   PubMed Web of Science ®Google Scholar
• Tvedt TH, Nepstad I, Bruserud O. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Expert Opin Investig Drugs. 2017 Mar;26(3):343–355. PubMed PMID: 28001095.
   PubMed Web of Science ®Google Scholar
• Link DC, Zutter M. The proto-oncogene c-fgr is expressed in normal mantle zone B lymphocytes and is developmentally regulated during myelomonocytic differentiation in vivo. Blood. 1995 Jan 15;85(2):472–479. PubMed PMID: 7812001.
   PubMed Web of Science ®Google Scholar
• Bruserud O, Glenjen N, Ryningen A, et al. In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines. Leuk Res. 2003 May;27(5):455–464. PubMed PMID: 12620297
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924–6932. PubMed PMID: 16203784.
   PubMed Web of Science ®Google Scholar
• Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542–5548. PubMed PMID: 16740687.
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Komai M, Itoh T, et al. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. Leuk Res. 2014 Jan;38(1):121–130. PubMed PMID: 24239173.
   PubMed Web of Science ®Google Scholar
• Gnoni A, Marech I, Silvestris N, et al. Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets. 2011 Apr;12(4):563–578. PubMed PMID: 21226671
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Hofmann WK, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res. 2003 Oct 15;9(13):4674–4681. PubMed PMID: 14581336.
   PubMed Web of Science ®Google Scholar
• Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008 Aug 15;112(4):1005–1012. PubMed PMID: 18477770.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23;116(12):2070–2077. PubMed PMID: 20466853; PubMed Central PMCID: PMCPMC4081177.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 1;121(23):4158–4164. PubMed PMID: 26308885; PubMed Central PMCID: PMCPMC4666803.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Yhim HY, Kwak JY, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol. 2016 Jun;27(6):1081–1088. PubMed PMID: 26951627.
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 1;110(7):2309–2315. PubMed PMID: 17496201.
   PubMed Web of Science ®Google Scholar
• Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010 Mar;85(3):164–170. PubMed PMID: 20131302.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011 Dec 15;118(25):6521–6528. PubMed PMID: 21931113.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coude MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016 Aug 11;128(6):774–782. PubMed PMID: 27121472; PubMed Central PMCID: PMCPMC5085255.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Othus M, O’Brien SM, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 2016 Dec 27;1(3):250–259. PubMed PMID: 29046900; PubMed Central PMCID: PMCPMC5642915.
   PubMed Web of Science ®Google Scholar
• Ravandi F. Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):22–27. PubMed PMID: 29222233; PubMed Central PMCID: PMCPMC6142602.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Foa R. Management of adult Ph-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015:406–413. PubMed PMID: 26637750.
   PubMed Web of Science ®Google Scholar
• Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar;89(3):282–287. PubMed PMID: 24779033; PubMed Central PMCID: PMCPMC4196860.
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Patel KP, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10;127(10):1269–1275. PubMed PMID: 26729897; PubMed Central PMCID: PMCPMC4786836.
   PubMed Web of Science ®Google Scholar
• Brattas MK, Lilleeng K, Hovland R, et al. Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. Biomark Res. 2018;6:33. PubMed PMID: 30479769; PubMed Central PMCID: PMCPMC6249888.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531–2541. PubMed PMID: 16775234.
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007 Mar;92(3):401–404. PubMed PMID: 17339191.
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Cortes JE, Hochhaus A, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity. Cancer. 2016 May 1;122(9):1398–1407. PubMed PMID: 26998677; PubMed Central PMCID: PMCPMC5071708.
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009 Aug;23(8):1398–1405. PubMed PMID: 19295545.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 1;122(23):3650–3656. PubMed PMID: 27479888; PubMed Central PMCID: PMCPMC5321539.
   PubMed Web of Science ®Google Scholar
• Wolach O, Amitai I, DeAngelo DJ. Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia. Br J Haematol. 2017 Dec;179(5):705–723. PubMed PMID: 29076138.
   PubMed Web of Science ®Google Scholar
• Wei G, Wang J, Huang H, et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017 Aug 18;10(1):150. PubMed PMID: 28821272; PubMed Central PMCID: PMCPMC5563021.
   PubMed Web of Science ®Google Scholar
• Hanif A, Wang ES, Thompson JE, et al. Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia. Leuk Lymphoma. 2018 Aug;59(8):2011–2013. PubMed PMID: 29251203.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011 Jun 20;29(18):2493–2498. PubMed PMID: 21576633.
   PubMed Web of Science ®Google Scholar
• Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015 Aug 6;126(6):746–756. PubMed PMID: 26065651.
   PubMed Web of Science ®Google Scholar
• Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017 Mar 30;543(7647):733–737. PubMed PMID: 28329763.
   PubMed Web of Science ®Google Scholar
• Christiansson L, Soderlund S, Mangsbo S, et al. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 2015 May;14(5):1181–1191. PubMed PMID: 25761894.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Fujisawa S, Yoshida C, et al. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol. 2015 Sep;90(9):819–824. PubMed PMID: 26103598.
   PubMed Web of Science ®Google Scholar
• Najima Y, Yoshida C, Iriyama N, et al. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. Leuk Res. 2018 Mar;66:66–72. PubMed PMID: 29407585.
   PubMed Web of Science ®Google Scholar
• Nerreter T, Kochel C, Jesper D, et al. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. Exp Hematol. 2014 Sep;42(9):773–82 e1–3. PubMed PMID: 24882272.
   PubMed Web of Science ®Google Scholar
• Chang MC, Cheng HI, Hsu K, et al. NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients With chronic myeloid leukemia. Front Immunol. 2018;9:3152. PubMed PMID: 30705677; PubMed Central PMCID: PMCPMC6344416.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyamoto T, Kamimura T, et al. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):e47–54. PubMed PMID: 25445469.
   PubMed Web of Science ®Google Scholar
• McCaig AM, Cosimo E, Leach MT, et al. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol. 2011 Apr;153(2):199–211. PubMed PMID: 21352196.
   PubMed Web of Science ®Google Scholar
• Giallongo C, Parrinello NL, La Cava P, et al. Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. J Cell Mol Med. 2018 Feb;22(2):1070–1080. PubMed PMID: 29218828; PubMed Central PMCID: PMCPMC5783858.
   PubMed Web of Science ®Google Scholar
• Heine A, Schilling J, Grunwald B, et al. The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib. Cancer Immunol Immunother. 2016 Mar;65(3):273–282. PubMed PMID: 26786874.
   PubMed Web of Science ®Google Scholar
• Ghelli Luserna Di Rora A, Iacobucci I, Imbrogno E, et al. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. Oncotarget. 2016 Aug 16;7(33):53377–53391. PubMed PMID: 27438145; PubMed Central PMCID: PMCPMC5288194.
   PubMedGoogle Scholar
• Fei F, Lim M, Schmidhuber S, et al. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib). Mol Cancer. 2012 Jun;21(11):42. PubMed PMID: 22721004; PubMed Central PMCID: PMCPMC3489684.
   PubMed Web of Science ®Google Scholar
• Fei F, Stoddart S, Groffen J, et al. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias. Mol Cancer Ther. 2010 May;9(5):1318–1327. PubMed PMID: 20388735; PubMed Central PMCID: PMCPMC2868097.
   PubMed Web of Science ®Google Scholar
• Duque-Afonso J, Lin CH, Han K, et al. CBP modulates sensitivity to dasatinib in pre-BCR(+) acute lymphoblastic leukemia. Cancer Res. 2018 Nov 15;78(22):6497–6508. PubMed PMID: 30262461; PubMed Central PMCID: PMCPMC6283070.
   PubMed Web of Science ®Google Scholar
• Gregory MA, Phang TL, Neviani P, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010 Jul 13;18(1):74–87. PubMed PMID: 20609354; PubMed Central PMCID: PMCPMC2904512.
   PubMed Web of Science ®Google Scholar
• Appelmann I, Rillahan CD, de Stanchina E, et al. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood. 2015 Feb 26;125(9):1444–1451. PubMed PMID: 25499760; PubMed Central PMCID: PMCPMC4342356.
   PubMed Web of Science ®Google Scholar
• Guo Y, Li Y, Xiang B, et al. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL. Biochem J. 2017 Dec 6;474(24):4153–4170. PubMed PMID: 29046392.
   PubMed Web of Science ®Google Scholar
• Gardner LA, Klawitter J, Gregory MA, et al. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 Sep;89(9):896–903. PubMed PMID: 24891015; PubMed Central PMCID: PMCPMC4134764.
   PubMed Web of Science ®Google Scholar
• Wang T, Cheng C, Peng L, et al. Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia. J Cell Mol Med. 2018 Mar;22(3):1614–1626. PubMed PMID: 29266867; PubMed Central PMCID: PMCPMC5824394.
   PubMed Web of Science ®Google Scholar
• Morishita T, Hayakawa F, Sugimoto K, et al. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget. 2016 Aug 30;7(35):56241–56252. PubMed PMID: 27494842; PubMed Central PMCID: PMCPMC5302911.
   PubMedGoogle Scholar
• Assi R, Kantarjian H, Short NJ, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):897–901. PubMed PMID: 28927784.
   PubMed Web of Science ®Google Scholar
• Visani G, Piccaluga P, Malagola M, et al. Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia. Leukemia. 2009 Sep;23(9):1687–1688. PubMed PMID: 19421228.
   PubMed Web of Science ®Google Scholar
• Vo TT, Lee JS, Nguyen D, et al. mTORC1 inhibition induces resistance to methotrexate and 6-mercaptopurine in Ph(+) and Ph-like B-ALL. Mol Cancer Ther. 2017 Sep;16(9):1942–1953. PubMed PMID: 28566433; PubMed Central PMCID: PMCPMC5619649.
   PubMed Web of Science ®Google Scholar